- All
- About MAA News Items
- Annual Conference News Items
- Art With Heart News Items
- Clinical Trials
- Get Involved News Items
- Health Professionals News Items
- Living with MG News Items
- MG Awareness Month News Items
- Patient Tool Kit
- Policy Makers News Items
- Understanding MG News Items
A message to the Australian MG community and in particular to patients in NSW from Associate Professor Stephen Reddel.
I am writing to let you know that I, Steve Reddel, is taking part as a Principal Investigator in a study for patients with generalized Myasthenia Gravis (gMG). The study is sponsored by Novartis. The study is a multicentre, double-blind, placebo-controlled phase III study of an oral medication in generalised myasthenia gravis patients with ACHR+…
Clinical Trial available in Australia!
The MAA is pleased to share with you that a clinical trial is now open for Australian participation. It will potentially offer an additional treatment pathway for myasthenia gravis patients. Please explore more details via the link provided. If you may be willing to participate, speak to your treating neurologist about progressing to the next…
EXPERT INSIGHTS: Myasthenia Gravis and symptom assessment tools to improve outcomes
How do we truly understand what life is like for someone living with myasthenia gravis? In this insightful webinar, Dr Carlo Antozzi, Senior Neurologist and Head of the Neuroimmunology and Neuromuscular Diseases Unit at the Besta Neurological Institute in Milan, takes us inside the evolving world of MG care – one where patients’ voices are…
PBAC resubmissions for Ultomiris® (Ravulizumab) and Zilbrysq® (Zilucoplan) for all Myasthenia Gravis patients
The Australian Myasthenia community have a once in a generation opportunity to support new treatments for generalised Myasthenia Gravis (gMG) which are listed on PBAC’s March 2025 agenda! The Myasthenia Alliance Australia (MAA) encourages Myasthenia patients and your carers or families/friends to consider making a personal submission highlighting your lived experience by 29 January 2025. Why? Because…
It is time to act! The PBAC lists 4 new gMG treatments for consideration at the March 2025 meeting!
The Pharmaceutical Benefits Advisory Committee (PBAC) has published its agenda for March 2025 and there are 4 generalised Myasthenia Gravis (gMG) treatments for consideration. Two are resubmissions and the other two are new requests for PBS listings. You can see the full agenda here. The closing date for consumer comments is Wednesday, 29th January 2025. The MAA…